← Leaderboards
Sabrina Paganoni
Massachusetts General Hospital
$36,168,406
Attributed
$128,144,567
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $41M · FY2022–25$50M$37.5M$25M$12.5M$0
'22
'23
'24
'25
Funding mix
By agency
NIH$128,144,567 · 4
By mechanism
U01$60,909,694 · 2
OT2$49,098,369 · 1
UF1$18,136,504 · 1
Top collaborators
- Suma Babu11 shared
- James Dale Berry11 shared
- Jinsy Andrews3 shared
- Jeremy M Shefner3 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Suma Babu$36,168,406
- Thomas F Delaney$3,171,852
- G Scott Gazelle$13,470,437
- Chin Hur$15,301,977
- John H Growdon$11,829,523
Others in their field
Other Rising Stars on “Persons”
- Mari Ostendorf · University Of Washington$51,931,230
- Brian Zavertnik · Palantir Technologies, Inc.$37,240,166
- Suma Babu · Massachusetts General Hospital$36,168,406
- Julia Louise Moore Vogel · Scripps Research Institute, The$32,252,685
- Cyrus Wadia · Activate Global, Inc.$24,000,000
- Jinsy Andrews · Columbia University Health Sciences$21,294,649
Research focus
PersonsAmyotrophic Lateral SclerosisSiteParticipantEnrollmentClinical TrialsDesignEnsureFda ApprovedBiologicalVital CapacitySafetyDoseMouse ModelHigh RiskClinicGeneral HospitalsDisease ProgressionCellsLightCohortCollaborationsBiological MarkersDatabases
Grant awards (11)
Access for All in ALS (ALL ALS) East Clinical Coordinating Center$14,357,590
OT2 · FY2025 · NS
An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with Pridopidine$7,928,222
U01 · FY2025 · NS · contact PI
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis$6,151,947
U01 · FY2025 · NS
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis$3,993,521
U01 · FY2025 · NS
Access for All in ALS (ALL ALS) East Clinical Coordinating Center$15,032,251
OT2 · FY2024 · NS
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis$11,665,635
U01 · FY2024 · NS
An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with Pridopidine$9,831,153
U01 · FY2024 · NS · contact PI
Access for All in ALS (ALL ALS) East Clinical Coordinating Center$19,708,528
OT2 · FY2023 · NS
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis$11,203,040
U01 · FY2023 · NS
An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with Pridopidine$10,136,176
U01 · FY2023 · NS · contact PI
An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with Amyotrophic Lateral Sclerosis$18,136,504
UF1 · FY2022 · NS · contact PI